<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Passive immunization with convalescent plasma (CP) during SARS-CoV-1 and SARS-CoV-2 infection.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reference</th><th valign="top">Virus</th><th valign="top">Antibody source</th><th valign="top">Number of patients</th><th valign="top">Efficacy</th><th valign="top">Safety</th></tr></thead><tbody><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib17">Cheng et al., 2005</xref></td><td valign="top">SARS-CoV-1</td><td valign="top">CP <break/>160&#8211;640 ml <break/>Seropositive titer range: <break/>160&#8211;2,560</td><td valign="top">80 patients with SARS</td><td valign="top">Better outcome with plasma before than after day 14</td><td valign="top">No immediate adverse effects</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib80">Yeh et al., 2005</xref></td><td valign="top">SARS-CoV-1</td><td valign="top">CP <break/>500 ml <break/>IF IgG titer <break/>&gt;640</td><td valign="top">3 hospital workers with SARS</td><td valign="top">Drop within 24 hr in viral load from ~ 10<sup>5</sup> to &lt; 1 RNA copies/ml</td><td valign="top">No significant side effects</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib62">Soo et al., 2004</xref></td><td valign="top">SARS-CoV-1</td><td valign="top">CP <break/>Ab titers not measured</td><td valign="top">19 (plasma) vs. 21 (methylprednisolone) SARS patients</td><td valign="top">Faster release, lower mortality with plasma than comparator</td><td valign="top">No immediate adverse effects</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib60">Shen et al., 2020</xref></td><td valign="top">SARS-CoV-2</td><td valign="top">CP 400 ml <break/>Ab binding <break/>&gt;1000 <break/>NAb&#160;&gt;&#160;40</td><td valign="top">5 COVID-19 patients</td><td valign="top">Reduced viral load, clinical improvement Release of 3/5</td><td valign="top">None reported</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib29">Duan et al., 2020</xref></td><td valign="top">SARS-CoV-2</td><td valign="top">CP 200 ml <break/>NAb&#160;&gt;&#160;640</td><td valign="top">10 COVID-19 patients</td><td valign="top">Virus undetectable in 7/10 <break/>Varying clinical, laboratory, radiological improvements</td><td valign="top">No adverse effects observed</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib83">Zhang et al., 2020</xref></td><td valign="top">SARS-CoV-2</td><td valign="top">CP 200&#8211;2,400 ml <break/>Ab not measured</td><td valign="top">4 COVID-19 patients</td><td valign="top">Negative PCR <break/>Pulmonological improvements <break/>Discharge of 3/4</td><td valign="top">No adverse effects observed</td></tr><tr><td valign="top"><break/><xref ref-type="bibr" rid="bib3">Ahn et al., 2020</xref></td><td valign="top">SARS-CoV-2</td><td valign="top">CP 2 &#215; 250 ml <break/>Binding IgG detected by ELISA</td><td valign="top">2 COVID-19 patients</td><td valign="top">Reduced sputum&#160;viral&#160;load Radiological and clinical improvements</td><td valign="top">No adverse effects observed</td></tr></tbody></table></table-wrap>